Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Matthew Bonaparte"'
Autor:
Delphine Planas, Lin Peng, Lingyi Zheng, Florence Guivel-Benhassine, Isabelle Staropoli, Françoise Porrot, Timothée Bruel, Jinal N. Bhiman, Matthew Bonaparte, Stephen Savarino, Guy de Bruyn, Roman M. Chicz, Penny L. Moore, Olivier Schwartz, Saranya Sridhar
Publikováno v:
Heliyon, Vol 10, Iss 5, Pp e27033- (2024)
Background: SARS-CoV-2 Omicron lineage contains variants with multiple sequence mutations relative to the ancestral strain particularly in the viral spike gene. These mutations are associated inter alia with loss of neutralization sensitivity to sera
Externí odkaz:
https://doaj.org/article/f8cfe1c63c354d758661ea45e79775c6
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2107-2116 (2021)
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Externí odkaz:
https://doaj.org/article/01e9265349dd42e8983c677b9b6022e8
Autor:
Vasco Liberal, Remi Forrat, Cong Zhang, Charles Pan, Matthew Bonaparte, Wushan Yin, Lingyi Zheng, Valeria Viscardi, Yukun Wu, Yasemin Ataman-Önal, Stephen Savarino, Catherine Chen
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 3 (2022)
ABSTRACT The World Health Organization has recommended prevaccination screening for prior dengue infection as the preferred approach prior to vaccination with the dengue vaccine CYD-TDV. These screening tests need to be highly specific and sensitive,
Externí odkaz:
https://doaj.org/article/28f48a43ca4e49449d8cd2a5d0e56b0d
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 3, Pp 523-529 (2020)
The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participant
Externí odkaz:
https://doaj.org/article/2620c153eb504ca4901aa9243abdbc49
Autor:
Stephen C De Rosa, Kristen W Cohen, Matthew Bonaparte, Bo Fu, Sanjay Garg, Catherine Gerard, Paul A Goepfert, Ying Huang, Daniel Larocque, M. Juliana McElrath, Daryl Morris, Robbert Van der Most, Guy deBruyn, Anke Pagnon
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 1, Pp n/a-n/a (2022)
Abstract Objectives We previously described the Phase I‐II evaluation of SARS‐CoV‐2 recombinant protein candidate vaccine, CoV2‐PreS‐dTM, with AF03‐ or AS03‐adjuvant systems (ClinicalTrials.gov, NCT04537208). Here, we further characteri
Externí odkaz:
https://doaj.org/article/a1cfa23ff2034272811b6634993dec22
Autor:
Lindsay N Carpp, Youyi Fong, Matthew Bonaparte, Zoe Moodie, Michal Juraska, Ying Huang, Brenda Price, Yingying Zhuang, Jason Shao, Lingyi Zheng, Laurent Chambonneau, Robert Small, Saranya Sridhar, Carlos A DiazGranados, Peter B Gilbert
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234236 (2020)
We previously showed that Month 13 50% plaque reduction neutralization test (PRNT50) neutralizing antibody (nAb) titers against dengue virus (DENV) correlated with vaccine efficacy (VE) of CYD-TDV against symptomatic, virologically-confirmed dengue (
Externí odkaz:
https://doaj.org/article/97e45ef310474973a6a72c954d268e82
Autor:
Claire Vigne, Martin Dupuy, Aline Richetin, Bruno Guy, Nicholas Jackson, Matthew Bonaparte, Branda Hu, Melanie Saville, Danaya Chansinghakul, Fernando Noriega, Eric Plennevaux
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 9, Pp 2004-2016 (2017)
Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV
Externí odkaz:
https://doaj.org/article/46d69039a41a48dfa3394ff3af1bccb7
Autor:
Maia A Rabaa, Yves Girerd-Chambaz, Kien Duong Thi Hue, Trung Vu Tuan, Bridget Wills, Matthew Bonaparte, Diane van der Vliet, Edith Langevin, Margarita Cortes, Betzana Zambrano, Corinne Dunod, Anh Wartel-Tram, Nicholas Jackson, Cameron P Simmons
Publikováno v:
eLife, Vol 6 (2017)
This study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-TDV, and thereby enabled virus genotype-specific estimates of vaccine efficacy (VE). Envelope gene sequences (
Externí odkaz:
https://doaj.org/article/fe150f1a003d4095828a01b5f93ae894
Autor:
Anke Harenberg, Aymeric de Montfort, Frédérique Jantet-Blaudez, Matthew Bonaparte, Florence Boudet, Melanie Saville, Nicholas Jackson, Bruno Guy
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004830 (2016)
BACKGROUND:Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant
Externí odkaz:
https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0
Autor:
Diana Leticia, Coronel-Martinez, Juliana, Park, Eduardo, López-Medina, María Rosario, Capeding, Andrés Angelo Cadena, Bonfanti, María Cecilia, Montalbán, Isabel, Ramírez, María Liza Antoinette, Gonzales, Betzana, Zambrano, Gustavo, Dayan, Zhenghong, Chen, Hao, Wang, Matthew, Bonaparte, Andrey, Rojas, Jenny Carolina, Ramírez, Mae Ann, Verdan, Fernando, Noriega
Publikováno v:
The Lancet Infectious Diseases. 22:901-911
Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primar